Skip to content

GRAIL, Inc. GRAL Stock-Based Comp

Stock-Based Comp at other companies

Abbott logo
AbbottABT
$317M+9.7%
Guardant Health logo
Guardant HealthGH
$47.61M+26.1%
Natera, Inc. logo
Natera, Inc.NTRA
$95.11M+22.2%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$52.71M+129%
Immunome logo
ImmunomeIMNM
$7.95M+39.5%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$11.93M-1.8%

Segments

By segment

See full
Reportable Segment$16.26M+5.2%

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s stock-based comp?
GRAIL, Inc. (GRAL) reported stock-based comp of $16.79M in Q1 2026.
How has GRAIL, Inc.'s stock-based comp changed year-over-year?
GRAIL, Inc.'s stock-based comp increased by 3.6% year-over-year, from $16.21M to $16.79M.
What is the long-term trend for GRAIL, Inc.'s stock-based comp?
Over 2 years (2022 to 2025), GRAIL, Inc.'s stock-based comp has grown at a -12.3% compound annual growth rate (CAGR), from $75.73M to $58.28M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.